MediciNova MNOV Faces Mixed Phase 2 Results Weighing Shares
MediciNova's MN-001 Phase 2 topline data show meaningful triglyceride reductions and HDL gains in 40 patients over 24 weeks, along with a favorable safety profile and modest weight loss. However, the liver fat measure did not reach statistical significance, prompting caution. Detailed analyses will guide the next phase of development.
View signal analysis